Ovarian cancer is a kind of malignant tumor originated from female ovary, which is generally classified into epithelial cancer, germ cell malignant tumor and sex cord mesenchymal stromal cell tumor according to different tissue origins, among which epithelial cancer is the most common type of ovarian malignant tumors, accounting for about 90% of the cases. As ovary is located in the deep pelvis, there are no specific symptoms in the early stage of the tumor, and patients are mostly in the advanced stage when they seek for diagnosis, with poor prognosis, which seriously threatens patients' life safety.
The treatment of ovarian cancer mainly includes surgery and chemotherapy, and the purpose of surgery is to resect the tumor, make a clear diagnosis, accurately stage, judge the prognosis and guide the treatment. In recent years, with the deepening of understanding of ovarian cancer genes at the molecular level and the gradual application of targeted drugs to the clinic, the precise treatment means of ovarian cancer have become more and more abundant.
PARP inhibitors are a class of drugs that have made remarkable progress in ovarian cancer treatment in recent years, and they can kill ovarian cancer cells with BRCA mutations or homologous recombination repair defects (HRD) by inhibiting PARPase activity. Currently, a variety of PARP inhibitors such as olaparib, niraparib, and pamiparib have been approved for the treatment of ovarian cancer, showing better efficacy especially in patients with BRCA mutation or HRD positivity. In addition, the ADC drug sorvetuximab soravtansine (MIRV), which targets FRα, has shown some effect in ovarian cancer treatment.
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Measured by its binding ability in a functional ELISA. Immobilized MSLN at 2 μg/ml can bind Anti-MSLN rabbit monoclonal antibody, the EC50 of the MSLN protein is 2.657-3.177 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized Human CLDN6 at 10 μg/ml can bind Anti-CLDN6/9 recombinant antibody (CSB-RA005508MA1HU), the EC50 is 1.501-2.035 ng/mL
Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized MUC16 at 10 μg/ml can bind MSLN (CSB-MP015044HUc9), the EC50 is 460.7-662.2 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
HEK293T/Human CLDN6 Stable Cell Line
CSB-SC005508HU
Untransfected HEK293T cells (green line) and transfected Human CLDN6 HEK293T stable cells (red line) were stained with anti-CLDN6/9 antibody (CSB-RA005508MA1HU) (2µg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
Overlay Peak curve showing Hela cells surface stained with CSB-RA878942MA1HU (red line) at 1:100.
Overlay Peak curve showing JK cells surface stained with CSB-RA006163MA1HU (red line) at 1:50.
Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.
Overlay histogram showing HepG2 cells stained with CSB-RA792129A0HU (red line) at 1:50.
Product Name | Code | Target | Species Reactivity | Tested Applications |
---|---|---|---|---|
CD247 Recombinant Monoclonal Antibody | CSB-RA244537A0HU | CD247 | Human | ELISA, FC |
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CD40 Recombinant Monoclonal Antibody | CSB-RA004936MA1HU | CD40 | Human | ELISA, IF, FC |
CD47 Recombinant Monoclonal Antibody | CSB-RA802124A0HU | CD47 | Human | ELISA, WB, IHC, IF |
CDH6 Recombinant Monoclonal Antibody | CSB-RA005055MA1HU | CDH6 | Human | ELISA |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA213310A0HU | CTLA4 | Human | ELISA, IHC |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA006163MA1HU | CTLA4 | Human, Mouse | ELISA, WB, IF, FC |
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody | CSB-RA007479A1092phHU | EGFR | Human | ELISA, WB |
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody | CSB-RA007479A1068phHU | EGFR | Human | ELISA, WB |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341A0HU | EGFR | Human | ELISA, WB, IHC, IF, FC |
EGFR Recombinant Monoclonal Antibody | CSB-RA794061A0HU | EGFR | Human | ELISA, WB, IHC |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341MA1HU | EGFR | Human | ELISA, IHC, FC |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA260392A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA1HU | ERBB2 | Human | ELISA |
Phospho-ERBB2 (Y1139) Recombinant Monoclonal Antibody | CSB-RA588766A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA2HU | ERBB2 | Human | ELISA, IHC |
FGFR3 Recombinant Monoclonal Antibody | CSB-RA555849A0HU | FGFR3 | Human | ELISA, IF |
FGFR3 Recombinant Monoclonal Antibody | CSB-RA966627A0HU | FGFR3 | Human | ELISA, WB |
IFNAR1 Recombinant Monoclonal Antibody | CSB-RA011046A0HU | IFNAR1 | Human | ELISA |
IL2RA Recombinant Monoclonal Antibody | CSB-RA011649MA1HU | IL2RA | Human | ELISA, IF |
MUC16 Recombinant Monoclonal Antibody | CSB-RA941216A0HU | MUC16 | Human | ELISA, IHC |
MUC16 Recombinant Monoclonal Antibody | CSB-RA973154A0HU | MUC16 | Human | ELISA, IHC |
NT5E Recombinant Monoclonal Antibody | CSB-RA978310A0HU | NT5E | Human | ELISA, IHC |
PDCD1 Recombinant Monoclonal Antibody | CSB-RA240597A0HU | PDCD1 | Human | ELISA, WB, IHC |
TOP1 Recombinant Monoclonal Antibody | CSB-RA792129A0HU | TOP1 | Human | ELISA, WB, IHC, FC, IP |
ZG16B Recombinant Monoclonal Antibody | CSB-RA836195MA1HU | ZG16B | Human, Macaca fascicularis | ELISA |
Tumour